Objective To observe the effects of probucol on blood levels of oxidative low density lipoprotein antibody (oxLDL-Ab), high-sensitive C-reactive protein (hs-CRP) and interleukin-18 (IL-18) in patients with acute coronary syndrome (ACS).
Methods 81 patients with ACS were divided randomly into a Probucol treatment group (p group, n=41) and a routine treatment group (R group, n=40). OxLDL-Ab, hs-CRP and IL-18 were respectively measured in peripheral blood before therapy. The level of OxLDL-Ab was measured again after a 4-week treatment. The levels of hs-CRP and IL-18 were measured again after 1-week treatment. The frequency of typical angina of p group and R group in the last week of treatment was analysed.
Results The levels of oxLDL-Ab, hs-CRP and IL-18 were obviously lower in p group compared with R group after treatment (p<0.05). The frequency of typical angina of p group in the last week of treatment was obviously lower than that of R group, and this was closely correlated with the decreased oxLDL-Ab values (p<0.05).
Conclusion Probucol had anti-oxidant and anti-inflammatory action in patients with ACS.
- acute coronary syndrome
- oxidative low density lipoprotein antibody
- high-sensitive C-reactive protein